Satellos Bioscience (MSLE) Retained Earnings (2023 - 2026)
Satellos Bioscience (MSLE) posted quarterly Retained Earnings of -$91.7 million for Q1 2026, down 211.92% quarter-over-quarter from $82.0 million in Q4 2025.
Satellos Bioscience (MSLE) Retained Earnings (2023 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Retained Earnings for 4 consecutive years, with -$91.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings changed N/A year-over-year to -$91.7 million; the TTM figure through Mar 2026 stood at -$91.7 million (changed N/A YoY), while the FY2025 annual figure was $82.0 million, up 243.56% from the prior year.
- Retained Earnings retreated to -$91.7 million in Q1 2026 per MSLE's latest filing, from $82.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $82.0 million in Q4 2025 and bottomed at -$91.7 million in Q1 2026.
- Historically, Retained Earnings has averaged -$24.7 million across 4 years, with a median of -$44.5 million in 2023.
- Annual changes were most pronounced in 2024 — Retained Earnings slumped 55.1% — and 2025, when it jumped 251.46%.
- Satellos Bioscience's Retained Earnings stood at -$34.9 million in 2023, then plunged by 55.1% to -$54.1 million in 2024, then surged by 251.46% to $82.0 million in 2025, then tumbled by 211.92% to -$91.7 million in 2026.
- Business Quant data shows MSLE's Retained Earnings at -$91.7 million in Q1 2026, $82.0 million in Q4 2025, and -$54.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 4.38 Bn |
| 10 | Satellos Bioscience | 205.19 Mn | 205.19 Mn | - | -103.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -91.74 Mn |
| Dec 31, 2025 | 81.97 Mn |
| Dec 31, 2024 | -54.12 Mn |
| Dec 31, 2023 | -34.89 Mn |